Spyre Therapeutics, Inc. (SYRE)Healthcare | Biotechnology | Waltham, United States | NasdaqGS
93.73 USD
-4.01
(-4.103%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 95.60 +1.87 (1.995%) ⇧ (July 13, 2026, 6:35 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 3:56 a.m. EDT
The most pressing concern is the combination of negative earnings and recent insider selling, which undermines the bullish analyst consensus. While the company holds a fortress-like balance sheet with substantial cash reserves, the business is burning cash with no profitable track record yet. Technically, the stock trades well above its moving averages, showing strong momentum, but the heavy put buying in the near term and the insider sales create significant friction for a confident entry. The long-term outlook remains cautious due to the lack of profitability and the stock's volatile history, making it a speculative hold rather than a core investment. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.079997 |
| AutoETS | 0.085815 |
| MSTL | 0.089791 |
| AutoARIMA | 0.154752 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 32% |
| H-stat | 25.70 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.053 |
| Excess Kurtosis | -0.04 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 8,139,631,104 |
| Forward P/E | -29.96 |
| Beta | 3.02 |
| Previous Name | Aeglea BioTherapeutics, Inc. |
| Website | https://www.spyre.com |
As of July 11, 2026, 3:56 a.m. EDT: Speculators are positioning defensively with heavy put volume in August expirations, suggesting downside protection is prioritized over aggressive upside bets. Implied volatility remains elevated across strikes, indicating expectations of continued price turbulence.
| Attribute | Value |
|---|---|
| 52 Week Change | 4.9561243 |
| Address1 | Building 23 |
| Address2 | Suite 105 221 Crescent Street |
| All Time High | 318.75 |
| All Time Low | 2.65 |
| Ask | 120.32 |
| Ask Size | 2 |
| Audit Risk | 10 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 1,662,360 |
| Average Daily Volume3 Month | 1,420,406 |
| Average Volume | 1,420,406 |
| Average Volume10Days | 1,662,360 |
| Beta | 3.024 |
| Bid | 68.42 |
| Bid Size | 2 |
| Board Risk | 6 |
| Book Value | 6.532 |
| City | Waltham |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 10 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 93.73 |
| Current Ratio | 8.971 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 96.77 |
| Day Low | 92.67 |
| Display Name | Spyre Therapeutics |
| Earnings Timestamp | 1,777,984,200 |
| Earnings Timestamp End | 1,785,846,600 |
| Earnings Timestamp Start | 1,785,846,600 |
| Ebitda Margins | 0.0 |
| Enterprise Value | 7,553,983,488 |
| Eps Current Year | -2.94651 |
| Eps Forward | -3.12849 |
| Eps Trailing Twelve Months | -2.12 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 79.7379 |
| Fifty Day Average Change | 13.992104 |
| Fifty Day Average Change Percent | 0.1754762 |
| Fifty Two Week Change Percent | 495.61243 |
| Fifty Two Week High | 102.06 |
| Fifty Two Week High Change | -8.329994 |
| Fifty Two Week High Change Percent | -0.0816186 |
| Fifty Two Week Low | 14.505 |
| Fifty Two Week Low Change | 79.225006 |
| Fifty Two Week Low Change Percent | 5.4619102 |
| Fifty Two Week Range | 14.505 - 102.06 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,460,035,800,000 |
| Float Shares | 81,049,810 |
| Forward Eps | -3.12849 |
| Forward P E | -29.960142 |
| Free Cashflow | -75,515,504 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 112 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.0 |
| Gross Profits | -171,652,992 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0586 |
| Held Percent Institutions | 0.93248004 |
| Implied Shares Outstanding | 86,841,253 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,694,131,200 |
| Last Split Factor | 1:25 |
| Long Business Summary | Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease); and SPY002 and SPY072 anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A). It is also developing SPY003, a clinical-stage program, which is in phase-2 clinical stage designed to bind to interleukin 23 (IL-23); SPY120, a combination of anti-a4ß7 and anti-TL1A mAbs; SPY130, a combination anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. The company was incorporated in 2013 and is based in Waltham, Massachusetts. |
| Long Name | Spyre Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 8,139,631,104 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_253892234 |
| Most Recent Quarter | 1,774,915,200 |
| Name Change Date | 2,026-07-13 |
| Net Income To Common | -148,703,008 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 8,487,864,068 |
| Number Of Analyst Opinions | 15 |
| Open | 95.72 |
| Operating Cashflow | -185,630,000 |
| Operating Margins | 0.0 |
| Overall Risk | 9 |
| Payout Ratio | 0.0 |
| Phone | 617 651 5940 |
| Post Market Change | 1.8699951 |
| Post Market Change Percent | 1.995087 |
| Post Market Price | 95.6 |
| Post Market Time | 1,783,982,137 |
| Prev Name | Aeglea BioTherapeutics, Inc. |
| Previous Close | 97.74 |
| Price Eps Current Year | -31.810514 |
| Price Hint | 2 |
| Price To Book | 14.349358 |
| Profit Margins | 0.0 |
| Quick Ratio | 8.796 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | -4.00999 |
| Regular Market Change Percent | -4.10272 |
| Regular Market Day High | 96.77 |
| Regular Market Day Low | 92.67 |
| Regular Market Day Range | 92.67 - 96.77 |
| Regular Market Open | 95.72 |
| Regular Market Previous Close | 97.74 |
| Regular Market Price | 93.73 |
| Regular Market Time | 1,783,972,800 |
| Regular Market Volume | 977,278 |
| Return On Assets | -0.22647 |
| Return On Equity | -0.31114 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 86,841,253 |
| Shares Percent Shares Out | 0.1571 |
| Shares Short | 13,640,183 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 12,627,576 |
| Short Name | Spyre Therapeutics, Inc. |
| Short Percent Of Float | 0.1681 |
| Short Ratio | 7.57 |
| Source Interval | 15 |
| State | MA |
| Symbol | SYRE |
| Target High Price | 135.0 |
| Target Low Price | 78.0 |
| Target Mean Price | 101.53333 |
| Target Median Price | 100.0 |
| Total Cash | 741,467,008 |
| Total Cash Per Share | 8.538 |
| Total Debt | 0 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.12 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 46.223625 |
| Two Hundred Day Average Change | 47.50638 |
| Two Hundred Day Average Change Percent | 1.027751 |
| Type Disp | Equity |
| Volume | 977,278 |
| Website | https://www.spyre.com |
| Zip | 2,453 |